Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations (NASDAQ:CELC)
CelcuityCelcuity(US:CELC) Seeking Alpha·2026-03-26 08:16

新闻内容分析 - 提供的文档内容不包含任何实质性的新闻、事件、财报或行业信息 [1]

Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations (NASDAQ:CELC) - Reportify